-
Safety of Beovu: A Lingering Issue Which Novartis Attempts to Counter with Recent Study Results
Recent Beovu Label Change in Europe Adds Information About Retinal Vasculitis and Retinal Vascular Occlusion (Posted by Tom Lamb at DrugInjuryWatch.com) In mid-September 2020 Novartis announced the results of a Phase 3…
-
Report on FDA Belviq Recall Decision Provides New Information About Excess Cancers Risks
Belviq Safety Data Review Found Higher Rates of Colorectal Cancer, Pancreatic Cancer, and Lung Cancer (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA's decision to request that the pharmaceutical company Eisai recall…
-
Drug Safety Issue: Elmiron Side Effects Risks for Eye and Vision Appear to be Greater Than Bladder Treatment Benefits
Patients Consider Whether Relief from Bladder Pain is Worth Possibility of Elmiron-Associated Maculopathy and Other Eye Problems (Posted by Tom Lamb at DrugInjuryWatch.com) Approved by the FDA way back in 1996, Elmiron…
-
Vascular Endothelial Growth Factor (VEGF) Inhibitors: Increased Risk Of Aneurysm And Artery Dissection
New Warnings Added To Drug Labels For All VEGF Inhibitors By UK's MHRA Already; FDA Is Evaluating Need For Regulatory Action (Posted by Tom Lamb at DrugInjuryWatch.com) On July 31, 2020 the…